Long-Term Effects of a 12-Week Exercise Training Program on Clinical Outcomes in Idiopathic Pulmonary Fibrosis

Lung

Volumn 193, Issue 3, 2015, Pages 345-354

  Vainshelboim, Baruch ^a,b   Oliveira, Jose ^b   Fox, Benjamin Daniel ^a,c   Soreck, Yafit ^a   Fruchter, Oren ^a,c   Kramer, Mordechai Reuven ^a,c  

^a RABIN MEDICAL CENTER   (Israel)

^b UNIVERSITY OF PORTO   (Portugal)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

6 Min walking test; Hospitalizations; Leg strength; Peak oxygen consumption; Quality of life; Survival

Indexed keywords

CORTICOSTEROID; PIRFENIDONE;

30 S CHAIR STAND TEST; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEATH; EXERCISE; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HOSPITALIZATION; HUMAN; LEG MOVEMENT; LONG TERM CARE; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROGNOSIS; PULMONARY REHABILITATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; CONVALESCENCE; EXERCISE TEST; EXERCISE TOLERANCE; IDIOPATHIC PULMONARY FIBROSIS; ISRAEL; KINESIOTHERAPY; LUNG; MORTALITY; MUSCLE STRENGTH; PATHOLOGY; PATHOPHYSIOLOGY; QUESTIONNAIRE; TIME FACTOR;

AGED; EXERCISE TEST; EXERCISE THERAPY; EXERCISE TOLERANCE; FEMALE; HOSPITALIZATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; ISRAEL; LUNG; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MUSCLE STRENGTH; QUALITY OF LIFE; RECOVERY OF FUNCTION; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929144533     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-015-9703-0     Document Type: Article

References (44)

1. Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. doi:10.1164/rccm.2009-040GL
2. Meltzer EB, Noble PW (2008) Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 3:8. doi:10.1186/1750-1172-3-8
3. King TE Jr, Bradford WZ, Castro-Bernardini S et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370(22):2083–2092. doi:10.1056/NEJMoa1402582
4. Noble PW, Albera C, Bradford WZ et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377(9779):1760–1769. doi:10.1016/S0140-6736(11)60405-4
5. Richeldi L, du Bois RM, Raghu G et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071–2082. doi:10.1056/NEJMoa1402584
6. American Thoracic Society (ATS), and the European Respiratory Society (ERS) (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161(2 Pt 1):646–664
7. Holland AE (2010) Exercise limitation in interstitial lung disease—mechanisms, significance and therapeutic options. Chron Respir Dis 7(2):101–111. doi:10.1177/1479972309354689
8. Spruit MA, Singh SJ, Garvey C et al (2013) An official american thoracic society/european respiratory society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 188(8):e13–e64. doi:10.1164/rccm.201309-1634ST
9. Swigris JJ, Kuschner WG, Jacobs SS et al (2005) Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 60(7):588–594. doi:10.1136/thx.2004.035220
10. Ries AL, Bauldoff GS, Carlin BW et al (2007) Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 131(5 Suppl):4S–42S. doi:10.1378/chest.06-2418
11. Nici L, Donner C, Wouters E et al (2006) American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 173(12):1390–1413. doi:10.1164/rccm.200508-1211ST
12. Kenn K, Gloeckl R, Behr J (2013) Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis—a review. Respiration 86(2):89–99. doi:10.1159/000354112
13. Vainshelboim B, Oliveira J, Yehoshua L et al (2014) Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration 88:378–388. doi:10.1159/000367899
14. Nishiyama O, Kondoh Y, Kimura T et al (2008) Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 13(3):394–399. doi:10.1111/j.1440-1843.2007.01205.x
15. Holland A, Hill C (2008) Physical training for interstitial lung disease. Cochrane Database Syst Rev 4:CD006322. doi:10.1002/14651858.CD006322.pub2
16. Holland AE, Hill CJ, Conron M et al (2008) Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 63(6):549–554. doi:10.1136/thx.2007.088070
17. Ryerson CJ, Cayou C, Topp F et al (2014) Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir Med 108(1):203–210. doi:10.1016/j.rmed.2013.11.016
18. Macintyre N, Crapo RO, Viegi G et al (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26(4):720–735. doi:10.1183/09031936.05.00034905
19. Miller MR, Crapo R, Hankinson J et al (2005) General considerations for lung function testing. Eur Respir J 26(1):153–161. doi:10.1183/09031936.05.00034505
20. Wanger J, Clausen JL, Coates A et al (2005) Standardisation of the measurement of lung volumes. Eur Respir J 26(3):511–522. doi:10.1183/09031936.05.00035005
21. Quanjer PH, Tammeling GJ, Cotes JE et al (1993) Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 16:5–40
22. American Thoracic Society (ATS), American College of Chest Physicians (ACCP) (2003) Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167:211–277. doi:10.1164/rccm.167.2.211
23. American College of Sports Medicine (2014) ACSM’s Guidelines for exercise testing and prescription, 9th edn. Lippincott Williams & Wilkins, Philadelphia
24. Ferrazza AM, Martolini D, Valli G et al (2009) Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration 77(1):3–17. doi:10.1159/000186694
25. Palange P, Ward SA, Carlsen KH et al (2007) Recommendations on the use of exercise testing in clinical practice. Eur Respir J 29(1):185–209. doi:10.1183/09031936.00046906
26. American Thoracic Society (ATS) Statement (2002) Guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117. doi:10.1164/rccm.166/1/111
27. Rikli RE, Jones CJ (2001) The senior fitness test manual. Human Kinetics, Champaign
28. Mahler DA, Wells CK (1988) Evaluation of clinical methods for rating dyspnea. Chest 93(3):580–586
29. Papiris SA, Daniil ZD, Malagari K et al (2005) The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med 99(6):755–761. doi:10.1016/j.rmed.2004.10.018
30. Peng S, Li Z, Kang J et al (2008) Cross-sectional and longitudinal construct validity of the Saint George’s Respiratory Questionnaire in patients with IPF. Respirology 13(6):871–879. doi:10.1111/j.1440-1843.2008.01359.x
31. Swigris JJ, Brown KK, Behr J et al (2010) The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 104(2):296–304. doi:10.1016/j.rmed.2009.09.006
32. Jenkins S, Hill K, Cecins NM (2010) State of the art: how to set up a pulmonary rehabilitation program. Respirology 15(8):1157–1173. doi:10.1111/j.1440-1843.2010.01849.x
33. Swigris JJ, Wamboldt FS, Behr J et al (2010) The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 65(2):173–177. doi:10.1136/thx.2009.113498
34. Florey CD (1993) Sample size for beginners. BMJ 306(6886):1181–1184
35. Vickers AJ, Altman DG (2001) Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 323(7321):1123–1124
36. Mukaka MM (2012) Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J 24(3):69–71
37. Altman DG, Bland JM (1998) Time to event (survival) data. BMJ 317(7156):468–469
38. Bland JM, Altman DG (1998) Survival probabilities (the Kaplan-Meier method). BMJ 317(7172):1572
39. Satagopan JM, Ben-Porat L, Berwick M et al (2004) A note on competing risks in survival data analysis. Br J Cancer 91(7):1229–1235. doi:10.1038/sj.bjc.6602102
40. Kenney WL, Wilmore J, Costill DL (2012) Physiology of sport and exercise, 5th edn. Human Kinetics, Champaign
41. Mujika I, Padilla S (2001) Cardiorespiratory and metabolic characteristics of detraining in humans. Med Sci Sports Exerc 33(3):413–421
42. Lemmer JT, Hurlbut DE, Martel GF et al (2000) Age and gender responses to strength training and detraining. Med Sci Sports Exerc 32(8):1505–1512
43. Mujika I, Padilla S (2000) Detraining: loss of training-induced physiological and performance adaptations. Part II: long term insufficient training stimulus. Sports Med 30(3):145–154
44. Otsuka T, Kurihara N, Fujii T et al (1997) Effect of exercise training and detraining on gas exchange kinetics in patients with chronic obstructive pulmonary disease. Clin Physiol 17(3):287–297